Skip to main content

Table 5 Baseline patient, tumor and prior surgery treatment characteristics according to non sentinel Node (NSN) involvement

From: Overview of the pathological results and treatment characteristics in the first 1000 patients randomized in the SERC trial: axillary dissection versus no axillary dissection in patients with involved sentinel node

Test

  

Non sentinel node involvment

Class

All (n = 443)

No (n = 358)

Yes (n = 84)

p-value

Age

Median [range]

59 [33–84]

59 [33–84]

59 [39–84]

0.828

<= 40

26 (5.87)

24 (6.70)

2 (2.38)

0.2864

41–75

391 (88.26)

314 (87.71)

76 (90.48)

 

> 75

26 (5.87)

20 (5.59)

6 (7.14)

 

Clinical T stage

T1

261 (59.32)

216 (60.67)

44 (53.01)

0.2384

T2

156 (35.45)

123 (34.55)

33 (39.76)

 

T3

9 (2.05)

5 (1.40)

4 (4.82)

 

T4

2 (0.45)

2 (0.56)

  

Tis/Tx

12 (2.73)

10 (2.81)

2 (2.41)

 

Tumor size (mm)

Median [range]

18 [0–80]

18 [0–70]

19 [0–80]

0.059

<=10

64 (14.61)

55 (15.58)

9 (10.71)

0.0465

10–30

331 (75.57)

269 (76.20)

61 (72.62)

 

> 30

43 (9.82)

29 (8.22)

14 (16.67)

 

Histology Type

Infiltrating ductal

358 (80.81)

290 (81.01)

67 (79.76)

0.4021

Infiltrating lobular

45 (10.16)

33 (9.22)

12 (14.29)

 

Mixed

13 (2.93)

11 (3.07)

2 (2.38)

 

Other

27 (6.09)

24 (6.70)

3 (3.57)

 

SBR Grade

Gr I

101 (23.60)

88 (25.51)

12 (14.63)

0.1104

Gr II

207 (48.36)

162 (46.96)

45 (54.88)

 

Gr III

120 (28.04)

95 (27.54)

25 (30.49)

 

LVI

No

134 (31.60)

100 (29.41)

34 (40.96)

0.0425

Yes

290 (68.40)

240 (70.59)

49 (59.04)

 

Capsular Effraction

No

327 (80.74)

276 (83.64)

50 (67.57)

0.0016

Yes

78 (19.26)

54 (16.36)

24 (32.43)

 

Hormonal receptors

Negative

44 (10.16)

36 (10.32)

8 (9.64)

0.8546

Positive

389 (89.84)

313 (89.68)

75 (90.36)

 

HER2 status

Negative

369 (86.42)

297 (86.34)

71 (86.59)

0.9530

Positive

58 (13.58)

47 (13.66)

11 (13.41)

 

Tumor subtype (RH/HER2)

RH+/HER2+

41 (9.72)

34 (10.00)

7 (8.64)

0.8656

RH+/HER2-

339 (80.33)

272 (80.00)

66 (81.48)

 

RH-/HER2+

16 (3.79)

12 (3.53)

4 (4.94)

 

RH-/HER2-

26 (6.16)

22 (6.47)

4 (4.94)

 

Harvested SN, number

Median [range]

2 [0–7]

2 [0–7]

2 [0–5]

0.650

0

2 (0.45)

1 (0.28)

1 (1.19)

0.4885

1

168 (37.92)

138 (38.55)

30 (35.71)

 
 

> 2

273 (61.63)

219 (61.17)

53 (63.10)

 

Involved SN

Median [range]

1 [0–4]

1 [0–4]

1 [0–4]

0.004

<=2

424 (98.60)

346 (99.43)

77 (95.06)

0.0026

> 2

6 (1.40)

2 (0.57)

4 (4.94)

 

ITC

22 (5.30)

21 (6.19)

1 (1.33)

0.0005

SN status

Micro

137 (33.01)

124 (36.58)

13 (17.33)

 

Macro

256 (61.69)

194 (57.23)

61 (81.33)

 

Mastectomie

77 (17.38)

60 (16.76)

17 (20.24)

0.4494

Breast surgery Type

Conservative

366 (82.62)

298 (83.24)

67 (79.76)

 

No

19 (4.45)

19 (5.51)

 

0.0297

Radiotherapy

Yes

408 (95.55)

326 (94.49)

82 (100.0)

 

No

126 (28.70)

116 (32.68)

10 (11.90)

0.0007

Chemotherapy

Neoadjuvant

16 (3.64)

13 (3.66)

3 (3.57)

 

Adjuvant

297 (67.65)

226 (63.66)

71 (84.52)

 

No

30 (8.72)

25 (9.06)

5 (7.35)

0.6553

Endocrine therapy

Yes

314 (91.28)

251 (90.94)

63 (92.65)

 

No

261 (85.02)

208 (84.90)

53 (85.48)

0.9081

Trastuzumab

Yes

46 (14.98)

37 (15.10)

9 (14.52)